Author

A. Arruda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 4 Assay:bulk RNA-seq· 3 Research Focus:gene regulatory network inference· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2

Frequent Co-Authors

A. Mitchell· 4 shared A. Murison· 3 shared M. D. Minden· 3 shared C. Arlidge· 2 shared E. Wagenblast· 2 shared H. Boutzen· 2 shared J. Dick· 2 shared J. E. Dick· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Mitchell

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells

J. L. Araujo, E. Wagenblast, V. Voisin, J. McLeod, O. I. Gan, S. Bansal, L. Jin, A. Mitchell, B. Gratton, S. Cutting, A. Arruda, M. Doedens, J.-M. Capo-Chichi, S. Abelson, M. D. Minden, , J. E. Dick

This study shows FLT3 is essential for ITD-mutated leukemic stem cells but not for normal hematopoietic stem cells, supporting targeted therapies for AML.

bioRxiv · Jun 30, 2024Cancer Biology

KDM6A loss sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition

L. D. Boila, S. Ghosh, S. K. Bandyopadhyay, L. Jin, A. Murison, A. G. X. Zeng, W. Shaikh, S. Bhowmik, S. S. N. A. Muddineni, M. Biswas, S. Sinha, S. S. Chatterjee, N. Mbong, O. I. Gan, A. Bose, , A. Sengupta

This study shows that KDM6A loss in AML increases sensitivity to PARP and BCL2 inhibitors, suggesting a new combination therapy approach for KDM6A-mutant AML.

bioRxiv · Jul 12, 2022 · PreprintCancer Biology

A primary patient-derived model for investigating functional heterogeneity within the human Leukemic Stem Cell Compartment

H. Boutzen, M. Chan-Seng-Yue, A. Murison, N. Mbong, E. Wagenblast, C. Arlidge, S. A. Madani Tonekaboni, E. Orouji, A. Arruda, A. Mitchell, F. Notta, M. Lupien, M. Minden, K. Kaufmann, J. Dick

bioRxiv · Mar 1, 2022 · PreprintCancer Biology

Transposable Elements Shape Stemness in Normal and Leukemic Hematopoiesis

G. Grillo, B. Nadorp, A. Qamra, A. Mitchell, C. Arlidge, A. Nand, N. Takayama, A. Murison, S. A. M. Tonekaboni, A. Arruda, J. Wang, M. Minden, O. Deniz, H. Boutzen, J. Dick, M. Lupien

The paper identifies transposable elements (TEs) as genetic drivers of stemness in normal and leukemic hematopoiesis, showing their role in maintaining stem cell properties through chromatin accessibility.

bioRxiv · Feb 16, 2021Cancer Biology

Immune Landscapes Predict Chemotherapy Resistance And Immunotherapy Response In Acute Myeloid Leukemia

J. Vadakekolathu, M. D. Minden, T. Hood, S. E. Church, S. Reeder, H. Altmann, A. H. Sullivan, E. J. Viboch, T. Patel, N. Ibrahimova, S. E. Warren, A. Arruda, Y. Liang, J. Muth, M. Schmitz, , S. Rutella

This study identifies immune subtypes in AML and shows that IFN-gamma profiles predict chemotherapy resistance and immunotherapy response.

bioRxiv · Jul 26, 2019Immunology